Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, China-Japan Friendship Hospital, Beijing, People's Republic of China.
National Clinical Research Center for Respiratory Diseases, Beijing, People's Republic of China.
Int J Chron Obstruct Pulmon Dis. 2021 Oct 22;16:2901-2910. doi: 10.2147/COPD.S325925. eCollection 2021.
To identify clinical features and outcomes associated with pulmonary heart disease among patients with chronic obstructive pulmonary disease exacerbation (COPD), which may help reduce economic burden accrued over hospital stay and shorten length of stay (LOS).
Totally, 4386 patients with acute exacerbation of COPD (AECOPD) classified into pulmonary heart disease (PHD) group and non-pulmonary heart disease group, were included from the ACURE registry, a prospective multicenter patient registry study. Clinical features and outcomes were compared between groups.
PHD patients had a more severe profile, including having higher scores of COPD assessment test and modified British Medical Research Council, worse lung function, more patients hospitalized more than once in the past year due to acute exacerbation of COPD, and more comorbidities. Furthermore, drug cost was higher and length of stay was longer in AECOPD patients with PHD.
AECOPD patients with PHD had a more severe profile and worse clinical outcomes, including higher drug cost and longer LOS. PHD is an independent risk factor of drug cost and LOS. Complicated with PHD in COPD/AECOPD patients with PHD means heavier disease burden and worse prognosis. It merits further study to focus on PHD management in COPD/AECOPD patients.
确定慢性阻塞性肺疾病急性加重（AECOPD）患者并发肺心病的临床特征和结局，以帮助降低住院费用和缩短住院时间（LOS）。
本研究纳入了来自 ACURE 注册登记研究的 4386 例 AECOPD 患者，分为肺心病（PHD）组和非肺心病组。比较两组患者的临床特征和结局。
PHD 患者的病情更严重，包括 COPD 评估测试和改良英国医学研究理事会评分更高、肺功能更差、过去一年因 COPD 急性加重住院次数更多、合并症更多。此外，PHD 患者的药物费用更高，住院时间更长。
AECOPD 合并 PHD 的患者病情更严重，临床结局更差，包括药物费用更高和 LOS 更长。PHD 是药物费用和 LOS 的独立危险因素。在 COPD/AECOPD 合并 PHD 的患者中，合并 PHD 意味着疾病负担更重、预后更差。值得进一步研究关注 COPD/AECOPD 患者的 PHD 管理。
